Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksADAM.L Regulatory News (ADAM)

  • There is currently no data for ADAM

Revised Redemption Agreement with Global Pharm

21 Oct 2015 08:49

RNS Number : 9379C
Adamas Finance Asia Limited
21 October 2015
 

Adamas Finance Asia Limited

(the "Company")

 

REVISED REDEMPTION AGREEMENT WITH Global Pharm

 

 

Further to the announcement made on 20 August 2015, the Company announces that through its 75% owned subsidiary, Blazer Delight Limited ("Blazer Delight"), it has entered into a revised agreement for the redemption of the remainder of the convertible bond held in the Chinese pharmaceutical company, Global Pharm Holdings Group Inc. ("Global Pharm") (the "Revised Agreement").

 

Through the previous redemption agreement announced on 18 December 2014, the Company was due to receive an initial payment of US$2.4 million on 31 December 2014, a further US$9 million on 31 March 2015 and a final payment of US$13.6 million on 30 April 2015, an aggregate of US$25 million. The initial payment was received, but the second and third payments were not made in accordance with the agreement. However, Global Pharm has since made further payments to Blazer Delight, which total US$5.44 million, net to the Company.

 

Under the Revised Agreement, Global Pharm has agreed to make payments to Blazer Delight of not less than US$750,000 per month, net to the Company. All amounts received under the Revised Agreement will be offset against the two payments which were due on 31 March 2015 and 30 April 2015 and which remain subject to penalty interest of 26% per annum, compounded on a daily basis. 

 

Subject to certain limited exclusions, Global Pharm Holdings Limited, LLC, a major shareholder in Global Pharm, has undertaken to transfer shares in Global Pharm to Blazer Delight in respect of any monthly payments that are not made on time and in full. For each monthly payment not made on time and in full, shares equivalent to 0.00375%, net to the Company, of the issued and outstanding share capital of Global Pharm, will be transferred on the first business day of each year commencing in 2016, subject to a maximum of 0.075%, net to the Company.

 

 

 

Enquiries:

 

Adamas Finance Asia Limited

John Croft

 

+44 (0) 1825 830587

Nominated Adviser

W H Ireland Limited

Tim Feather

Liam Gribben

+44 (0) 113 394 6600

Broker

Edmond de Rothschild Securities (UK) Limited

 

+44 (0) 20 7845 5950

John Armstrong-Denby

Hiroshi Funaki

Public Relations Advisers

Ryan Communication (Hong Kong)

Scott McFarlane

 

+852 6297 3801

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRDFLBLEBFZFBZ
Date   Source Headline
26th Apr 20117:00 amRNSRepurchase of Fortel shares
12th Apr 20112:04 pmRNSResult of Meeting
23rd Mar 20116:21 pmRNSPosting of Circular
18th Mar 20113:30 pmRNSStrategic Investment
7th Mar 20114:45 pmRNSDirector/PDMR Shareholding
28th Feb 20116:27 pmRNSHolding(s) in Company
18th Feb 20112:31 pmRNSChange of Auditor
18th Feb 20112:04 pmRNSDirector/PDMR Shareholding
29th Dec 201012:46 pmRNSHolding(s) in Company
2nd Dec 20109:35 amRNSHolding(s) in Company
16th Nov 20104:00 pmRNSTR-1: Notification of Major Interest in Shares
1st Nov 20109:40 amRNSStrategic investment in online education
23rd Sep 20107:00 amRNSInterim Results
29th Jul 201011:45 amRNSResult of AGM
8th Jul 20103:23 pmRNSAppointment of Joint Broker
7th Jul 201012:41 pmRNSNotice of AGM
28th Jun 20102:10 pmRNSFinal Results
3rd Jun 20101:49 pmRNSResult of General Meeting
18th May 201010:00 amRNSBonus Issue
8th Mar 20107:00 amRNSFortel Value Up 26% to US$23.9M

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.